Oncoinvent ASA (OSL:ONCIN)
Norway · Delayed Price · Currency is NOK | Market Cap | 218.10M |
| Revenue (ttm) | 28.07M +246.4% |
| Net Income | -155.07M |
| EPS | -1.25 |
| Shares Out | 4.48M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,107 |
| Average Volume | 3,952 |
| Open | 47.00 |
| Previous Close | 47.40 |
| Day's Range | 45.20 - 48.70 |
| 52-Week Range | 40.10 - 134.80 |
| Beta | n/a |
| RSI | 54.71 |
| Earnings Date | Apr 22, 2026 |
About Oncoinvent ASA
Oncoinvent ASA, a clinical stage company, develops radiopharmaceutical therapies against cancer. Its lead product candidate is Radspherin, an alpha-radiation therapy candidate for treating cancer that have spread to body cavities, including peritoneum in two phase 1/2a trials and one randomized phase 2 trial. The company is based in Oslo, Norway. [Read more]
Financial Performance
In 2025, Oncoinvent ASA's revenue was 28.07 million, an increase of 246.40% compared to the previous year's 8.10 million. Losses were -155.07 million, 10.6% more than in 2024.
Financial StatementsNews
Oncoinvent ASA Earnings Call Transcript: Q1 2026
Phase II trial recruitment for Radspherin is progressing well, with 37 patients enrolled and cash reserves supporting operations into 2027. A new Chinese patent was secured, and strategic partnerships are being pursued to extend runway and advance to pivotal studies.
Oncoinvent ASA Transcript: Investor update
Phase II trial recruitment for Radspherin is progressing well, with 37 patients enrolled and cash reserves supporting operations into 2027. A new Chinese patent was secured, and strategic partnerships are being pursued to extend runway and advance to pivotal studies.
Oncoinvent ASA Earnings Call Transcript: Q4 2025
Positive phase I ovarian cancer data and strong phase II recruitment marked the period, supported by a NOK 130 million equity raise and a merger, resulting in a NOK 180 million year-end cash balance and a runway into 2027. Clinical expansion and strategic partnerships remain key priorities.
Oncoinvent ASA: Second half 2025 results
OSLO, Norway, Feb. 26, 2026 /PRNewswire/ -- Oncoinvent (OSE: ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity aft...
Oncoinvent ASA Transcript: EGM 2026
Shareholders approved a 100-to-1 reverse share split, reduction of nominal share value, and board authorizations for future capital increases. The meeting addressed rationale for these changes, future listing options, and ongoing recruitment updates, with all proposals passing.
Oncoinvent ASA Transcript: EGM 2025
Shareholders approved all agenda items, including a share capital reduction and subsequent increase to facilitate a NOK 130 million rights issue at a new share price of NOK 0.5, with nearly unanimous support for all resolutions.
Oncoinvent ASA Earnings Call Transcript: Q3 2025
Phase I trials in ovarian and colorectal cancer showed strong safety and efficacy signals for Radspherin, with a merger and rights issue extending cash runway into 2027. Phase II ovarian cancer trial recruitment is accelerating, with interim data expected in 2026.
Oncoinvent ASA Transcript: M&A Announcement
A merger will create a well-funded, publicly listed radiopharma company focused on peritoneal metastases, with BerGenBio shareholders owning 25% and Oncoinvent 75%. The deal secures funding into 2027, accelerates clinical milestones, and is backed by both boards and major shareholders.
BerGenBio ASA (STU:7BG0) Q4 2024 Earnings Call Highlights: Strategic Review and Financial ...
BerGenBio ASA (STU:7BG0) Q4 2024 Earnings Call Highlights: Strategic Review and Financial Management in Focus
Oncoinvent ASA Earnings Call Transcript: Q4 2024
Discontinuation of the first-line NSCLC study followed weak efficacy data, with no overall responses in phase II and a 30% disease control rate, prompting a strategic review of assets and future options. Year-end cash was NOK 140 million, with a focus on cost efficiency.
Oncoinvent ASA Earnings Call Transcript: Q3 2024
Phase 1b enrollment for Bemcentinib in STK11-mutated NSCLC is complete, with strong safety and therapeutic data. Cash burn remains below guidance, funding operations into Q3 2025. Interim Phase 2a results are expected in early 2025.
Oncoinvent ASA Earnings Call Transcript: Q2 2024
Advanced clinical development in STK11-mutated NSCLC with phase II-A on track and innovative synthetic control arm established. Strong cash position funds operations through summer 2025, with pivotal study planning underway and multiple data readouts expected in the coming year.